Research Advance of Chinese Medicine in Treating Atherosclerosis: Focus on Lipoprotein-Associated Phospholipase A2.
10.1007/s11655-023-3611-6
- Author:
Lu-Ming WANG
1
;
Wen-Lan ZHANG
1
;
Nuan LYU
1
;
Yan-Rong SUO
2
;
Lin YANG
1
;
Bin YU
3
;
Xi-Juan JIANG
1
Author Information
1. School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
2. Department of Traditional Chinese Medicine, Ganzhou People's Hospital, Ganzhou, Jiangxi Province, 341000, China.
3. School of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. yubin_771115@hotmail.com.
- Publication Type:Review
- Keywords:
Chinese medicine;
apoptosis;
atherosclerosis;
inflammation;
lipoprotein-associated phospholipase A2;
oxidative stress
- MeSH:
Humans;
1-Alkyl-2-acetylglycerophosphocholine Esterase;
Medicine, Chinese Traditional;
Atherosclerosis/drug therapy*;
Lipoproteins;
Plaque, Atherosclerotic;
Biomarkers
- From:
Chinese journal of integrative medicine
2024;30(3):277-288
- CountryChina
- Language:English
-
Abstract:
As a serious cardiovascular disease, atherosclerosis (AS) causes chronic inflammation and oxidative stress in the body and poses a threat to human health. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a member of the phospholipase A2 (PLA2) family, and its elevated levels have been shown to contribute to AS. Lp-PLA2 is closely related to a variety of lipoproteins, and its role in promoting inflammatory responses and oxidative stress in AS is mainly achieved by hydrolyzing oxidized phosphatidylcholine (oxPC) to produce lysophosphatidylcholine (lysoPC). Moreover, macrophage apoptosis within plaque is promoted by localized Lp-PLA2 which also promotes plaque instability. This paper reviews those researches of Chinese medicine in treating AS via reducing Lp-PLA2 levels to guide future experimental studies and clinical applications related to AS.
